NANOSPRESSO is dedicated to revolutionising personalised nanomedicine, with a focus on RNA-based treatments that are produced locally, at the point of care. This six-year project, launched in September 2022, aims to bring life-changing therapies closer to patients, particularly those with rare and orphan diseases who currently have limited treatment options. By enabling the local production of nucleic acid nanomedicines within hospitals, NANOSPRESSO makes advanced, personalised healthcare more accessible, economically feasible, and rapidly available.
About NANOSPRESSO
The project leverages cutting-edge microfluidic technology to facilitate the decentralised production of RNA therapies, such as those for methylmalonic acidemia and Crigler-Najjar syndrome. These rare conditions, which often lack effective treatments, are central to our mission to make personalised healthcare a reality for those who need it most.
The Vision Behind NANOSPRESSO
At its core, NANOSPRESSO aims to reinvent the concept of compounding in hospitals by empowering healthcare providers to create advanced RNA-based treatments on-site, specifically tailored to the genetic needs of their patients. The project recognises that traditional pharmaceutical production is often too slow, expensive, and inflexible to meet the needs of patients with rare diseases. By enabling local production of RNA-based nanomedicines, we are reducing production timelines, lowering costs, and ensuring that patients receive personalised treatments quickly and effectively.
Our Collaborative Approach
NANOSPRESSO isn’t just about developing technology; it’s about creating a strong network of collaboration across Europe. Our project brings together leading scientists, clinicians, and industry stakeholders, building a platform that integrates the entire value chain—from fundamental research and development to clinical applications. We work together to ensure that every RNA nanomedicine produced throughout the project and beyond meets the highest standards of quality, safety, and efficacy. This includes ensuring compliance with regulatory standards to facilitate the integration of personalised nanomedicine into healthcare.
The Impact of NANOSPRESSO
NANOSPRESSO’s impact reaches beyond the technology it develops. By making RNA-based treatments locally accessible, we are removing the barriers that have prevented patients with rare diseases from receiving timely care. The project focuses on diseases that currently lack effective treatments and aims to establish a new paradigm in personalised healthcare—one where hospitals themselves have the capability to manufacture the treatments they administer. This approach can transform patient outcomes, improve quality of life, and help build a more resilient and adaptable healthcare system across Europe.
Join the NANOSPRESSO Community
Explore our mission, learn more about our partners, and see how you can contribute to the NANOSPRESSO vision of personalised nanomedicine.
